- AstraZeneca said its lung cancer drug received marketing approval in China as a 1st-line treatment based on results from a clinical trial.

In the Flaura trial, 1st-line use of lung cancer drug Tagrisso provided a statistically-significant and clinically- meaningful improvement in progression-free survival, increasing the time patients lived without disease progression or death by a median of 18.9 months versus 10.2 months for those taking standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) medicines.

'The Flaura trial has demonstrated the potential of Tagrisso as a new standard of care and as an important new 1st-line treatment option for non-small cell lung cancer patients in China, where approximately 30-40% are diagnosed with an EGFR mutation - more than any other country in the world,' said Dave Fredrickson, Executive Vice President, Oncology.

Story provided by